Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00500617 · ClinicalTrials.gov registry record
Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree
A clinical trial of Cardiovascular Diseases and Coronary Artery Disease, sponsored by CardioDx.
- Completed
- Registry status
- 4,350
- Enrollment target
- 10
- Study locations
NCT00500617 is a study of Cardiovascular Diseases and Coronary Artery Disease that has completed, run by CardioDx. The registered enrollment target is 4,350 participants, below the 26,960-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (84% lower). The trial reports 10 study locations across 9 states.
The verdict
NCT00500617, a study of Cardiovascular Diseases and Coronary Artery Disease, has completed, sponsored by CardioDx.
- COMPLETED
- Registry status
- 4,350 participants
- Enrollment target
- 10
- Study locations
Study Summary
The PREDICT study is to develop and validate a diagnostic blood ASGES (age, sex, gene expression score) or Corus CAD for atherosclerotic coronary artery disease (CAD). The Corus CAD (Age/Sex/Gene Expression score - ASGES) will use quantitative real-time PCR (RT-PCR) to quantify the expression of multiple genes from circulating peripheral blood cells to assess the presence of clinically significant CAD in a patient.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Corus CAD (ASGES)
Study Locations (10)
California
- CV Medical Group Southern California - Beverly Hills
- Scripps HealthCare - La Jolla
Alaska
- Alaska Heart Institute - Anchorage
District of Columbia
- Washington Hospital Medical Center - Washington D.C.
Georgia
- Fuqua Heart Center of Atlanta - Atlanta
Minnesota
- Minneapolis Heart Institute - Minneapolis
North Carolina
- Duke University Medical Center - Durham
Pennsylvania
- Allegheny Hospital - Pittsburgh
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,350 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00500617
The ClinicalTrials.gov registry entry for NCT00500617 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4,350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,960-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (84% lower). The listed sponsor is CardioDx, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Corus CAD (ASGES) is the first listed.
NCT00500617 reports 10 study locations spanning 9 distinct geographic areas - top geographies include California, Alaska, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00500617 about?
NCT00500617 is a clinical study titled "Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree". The PREDICT study is to develop and validate a diagnostic blood ASGES (age, sex, gene expression score) or Corus CAD for atherosclerotic coronary artery disease (CAD). The Corus CAD (Age/Sex/Gene Expression score - ASGES) will use quantitative real-time PCR (RT-PCR) to quantify the expression of mul...
What is the current status of trial NCT00500617?
This trial is currently completed. The enrollment target is 4,350 participants. The study started on 2007-07. Estimated completion is 2011-09.
What conditions does trial NCT00500617 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Coronary Artery Disease, Chest Pain, Coronary Heart Disease, Angina Pectoris.
What interventions are being tested in trial NCT00500617?
The interventions under investigation include: Corus CAD (ASGES) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT00500617?
This trial is sponsored by CardioDx, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00500617 being conducted?
This trial has 10 study locations across Alaska, California, District of Columbia, Georgia, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
RECRUITING · NA
-
TRANSCRIBE (Transcriptomic Analysis of Left Ventricular Gene Expression)
RECRUITING
-
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.